The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF Pharmaceuticals, which recorded the highest increases in message volume among ...

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene ...

Shares of Sarepta Therapeutics SRPT surged more than 30% in after-market trading yesterday after the company announced a ...

Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...

Shares of Sarepta Therapeutics plummeted Friday following a report that a third patient has died during a clinical trial for ...

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...

Biopharma stock Sarepta Therapeutics Inc (NASDAQ:SRPT) is soaring today, up 20.6% at $22.17 at last glance. The ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. (“Sarepta” ...